Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" ...

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By ...

Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...

Regenerative medicine is shifting healthcare beyond aesthetics as doctors explain how cellular therapies restore healing, ...

Researchers led by Dr. Claire Foldi at Monash University have discovered that psilocybin, the psychoactive compound found in magic mushrooms, produces subtle but distinct effects on social behavior ...

Biosimilar natalizumab (Tyruko) is approved by EMA, US FDA, MHRA etc. and article is intended only for the HCP audience in ...

Researchers discovered that psilocybin produces subtle, context-dependent effects on social behavior and IL-6 mediated inflammation in female mice. Activity-based anorexia (ABA) mice exhibited ...

Physicists are closing in on a strange, hidden influence that does not fit neatly into the four familiar forces of nature, ...

ABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025.